Gene · 6607
Papers3,510
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 3,510
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Risdiplam treatment following onasemnogene abeparvovec in individuals with spinal muscular atrophy: a multicenter case series. | BMC Neurol | 2025 | 40624473 | PubTator, text mining | PubMed |
| Gestational Age at Birth and Clinical Manifestations of Spinal Muscular Atrophy. | Neurology | 2025 | 40577675 | PubTator, text mining | PubMed |
| Longitudinal Assessment of 4-Year HFMSE Changes in SMA II and III Patients Treated With Nusinersen. | Eur J Neurol | 2025 | 40576143 | PubTator, text mining | PubMed |
| Incidence of Homozygous SMN2 Deletion in Japan: Cross-Reactivity of SMN2 Primers with SMN1 Sequence Causes False Negatives in Real-Time PCR Screening. | Genes (Basel) | 2025 | 40565604 | PubTator, text mining | PubMed |
| Power mobility in children with motor impairments: adaptations in electric toy cars to improve handling in natural environments - a case series. | Disabil Rehabil Assist Technol | 2025 | 40536252 | PubTator, text mining | PubMed |
| Single Antisense Oligonucleotides Correct Diverse Splicing Mutations in Hotspot Exons. | Proc Natl Acad Sci U S A | 2025 | 40523177 | PubTator, text mining | PubMed |
| Efficacy and preliminary safety assessment of EXG001-307 AAV gene therapy for spinal muscular atrophy. | Mol Ther Methods Clin Dev | 2025 | 40458203 | PubTator, text mining | PubMed |
| Salbutamol in 5q spinal muscular atrophy: a systematic review and meta-analysis of efficacy and safety. | Eur J Pediatr | 2025 | 40410501 | PubTator, text mining | PubMed |
| Comprehensive analysis across SMN2 excludes DNA methylation as an epigenetic biomarker for spinal muscular atrophy. | iScience | 2025 | 40384931 | PubTator, text mining | PubMed |
| Long-Term Effects of Nusinersen Dosing Frequency on Adult Patients With Spinal Muscular Atrophy: Efficacy of a 6-Month Dosing Interval. | Brain Behav | 2025 | 40320994 | PubTator, text mining | PubMed |
| Analysis of Eye Movements in Adults with Spinal Muscular Atrophy. | Medicina (Kaunas) | 2025 | 40282862 | PubTator, text mining | PubMed |
| Newborn screening facilitates early theranostics and improved spinal muscular atrophy outcome: five-year real-world evidence from Taiwan. | Orphanet J Rare Dis | 2025 | 40275389 | PubTator, text mining | PubMed |
| Newborn screening for spinal muscular atrophy: The potential of digital polymerase chain reaction technique. | Mol Genet Metab | 2025 | 40267637 | PubTator, text mining | PubMed |
| Clinical Application of Risdiplam in 5q Spinal Muscular Atrophy: A Narrative Review. | Br J Hosp Med (Lond) | 2025 | 40265545 | PubTator, text mining | PubMed |
| Benchmarking of germline copy number variant callers from whole genome sequencing data for clinical applications. | Bioinform Adv | 2025 | 40248358 | PubTator, text mining | PubMed |
| Merging High-Throughput, Amplicon-Based Second and Third Generation Sequencing Data: An Integrative and Modular Data Analysis Framework for Haplotype Prediction and Output Evaluation. | Int J Mol Sci | 2025 | 40244459 | PubTator, text mining | PubMed |
| Photoaffinity enabled transcriptome-wide identification of splice modulating small molecule-RNA binding events in native cells. | RSC Chem Biol | 2025 | 40226337 | PubTator, text mining | PubMed |
| Spectrum of Phenotypes in SMA Patients With 4 SMN2 Copies in the French Population: Registre SMA France. | Neurol Genet | 2025 | 40212804 | PubTator, text mining | PubMed |
| In utero therapy for spinal muscular atrophy: closer to clinical translation. | Brain | 2025 | 40193572 | PubTator, text mining | PubMed |
| What did we learn from new treatments in SMA? A narrative review. | Acta Myol | 2025 | 40183438 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6607/papers?page=10